GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » Short-Term Debt

Galapagos NV (FRA:GXE) Short-Term Debt : €0.0 Mil (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Short-Term Debt?

Galapagos NV's Short-Term Debt for the quarter that ended in Sep. 2024 was €0.0 Mil.


Galapagos NV Short-Term Debt Historical Data

The historical data trend for Galapagos NV's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Short-Term Debt Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galapagos NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Galapagos NV Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Galapagos NV Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Galapagos NV Headlines

No Headlines